John Niven
Dermatology · Miami Beach, FLNPI 1336167634
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $30 of the $36 with a category attached, or 83.5%. 3 manufacturers reported payments, led by LEO Pharma Inc. at 41.8% of the total. That places this record below the midpoint for dermatology clinicians in FL, where the typical reported total is $2,563.
Across 3 payments — averaging $11.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- LEO Pharma Inc.$15
- Lilly USA, LLC$15
- Pfizer$6
Across 1,187 payments — averaging $2615.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$767K
- Takeda Pharmaceuticals U.S.A., Inc.$707K
- Dermavant Sciences, Inc.$448K
- Sanofi$240K
- Sun Pharmaceutical Industries Inc.$196K
- Arcutis Biotherapeutics, Inc.$134K
- plus $614K from 9 others
What the payments were for
- Food & beverage$3084%
- Education$616%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| LEO Pharma Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Pfizer | 1 | $6 |
How this compares
$36 in reported general payments places this provider in the 5th percentile of 1,147 dermatology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Taltz AutoinjectorIxekizumab | 12 | $89,107 |
| EnbrelEtanercept | 29 | $48,277 |
| Dupixent SyringeDupilumab | 22 | $45,036 |
| HumiraAdalimumab | 12 | $44,680 |
| Enbrel SureclickEtanercept | 14 | $27,737 |
| Fluocinonide | 1,941 | $15,880 |
| Hadlima PushtouchAdalimumab-Bwwd | 22 | $14,524 |
| MounjaroTirzepatide | 11 | $13,851 |
| Triamcinolone Acetonide | 2,042 | $11,192 |
| Mometasone Furoate | 923 | $9,166 |
| Calcipotriene | 120 | $7,573 |
| Halobetasol Propionate | 337 | $7,159 |
| Ketoconazole | 966 | $6,715 |
| Pimecrolimus | 70 | $5,388 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 791 | $4,450 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $15 | $13,85111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 1,147 dermatology providers in Florida.
Other dermatology in Miami Beach
- Roberta del CampoMiami Beach$207K
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
- Marc IngleseTallahassee$989K
- Jeremy GreenCoral Gables$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.